🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Cementos Pacasmayo declares annual dividend

EditorIsmeta Mujdragic
Published 10/29/2024, 09:53 AM
CPAC
-

In a recent filing with the SEC, Cementos Pacasmayo S.A.A., a hydraulic cement manufacturer based in Peru, announced its annual dividend. The report, submitted today, details the company's decision to distribute dividends to its shareholders.

The document, a Form 6-K, serves as a report for foreign private issuers in compliance with the SEC's rules. The company, listed under the commission file number 001-35401, operates under the jurisdiction of the Republic of Peru, with its principal executive office located in Lima.

Carlos Jose Molinelli Mateo, identified as the Stock Market Representative, signed the report on behalf of Cementos Pacasmayo S.A.A., confirming the authenticity and authorization of the information provided.

While the announcement marks a significant event for the company and its shareholders, the filing did not disclose the specific amount of the dividend. This move is part of the company's regular financial practices, aligning with its fiscal policies and shareholder distribution strategies.

This report is based solely on the information provided in the SEC filing.

In other recent news, Cementos Pacasmayo, a leading cement company, faced a downgrade by JPMorgan from Neutral to Underweight due to potential challenges. JPMorgan set a price target of $6.00 and noted the limited scope for EBITDA margin improvement after an expected gain to 28% for the current year.

The firm also highlighted weak volume sales, constraining significant EBITDA growth, with projections of 8% and 3% for 2024 and 2025, respectively. Despite these concerns, Cementos Pacasmayo stands out with a substantial dividend payout, offering a 10.9% yield for the current year.

In contrast, JPMorgan upgraded UCB SA's stock from Neutral to Overweight, raising the price target to €200.00 from €150.00. The firm emphasized UCB's growth potential, expecting a compound annual growth rate in earnings per share of 31% from 2024 to 2027, and noted potential growth from further development of Atopic Dermatitis treatments UCB9741 and UCB1381.

In additional developments, Cementos Pacasmayo announced its consolidated financial results for the second quarter of 2024, reflecting the company's financial position and operations. These recent developments provide insights into the companies' performances and future prospects, as projected by analysts.

InvestingPro Insights

Cementos Pacasmayo's recent dividend announcement aligns with its strong track record of shareholder returns. According to InvestingPro data, the company boasts a high dividend yield of 8.31%, significantly above market averages. This is complemented by an InvestingPro Tip highlighting that Cementos Pacasmayo has maintained dividend payments for 18 consecutive years, underscoring its commitment to consistent shareholder returns.

The company's financial health appears robust, with a P/E ratio of 11.58, suggesting it's trading at a relatively low earnings multiple. This is further supported by an InvestingPro Tip indicating that the stock's valuation implies a strong free cash flow yield. For investors seeking more comprehensive analysis, InvestingPro offers 8 additional tips that could provide deeper insights into Cementos Pacasmayo's investment potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.